A Model for Dimerization of the SOX Group E Transcription Factor Family
Group E members of the SOX transcription factor family include SOX8, SOX9, and SOX10. Preceding the high mobility group (HMG) domain in each of these proteins is a thirty-eight amino acid region that supports the formation of dimers on promoters containing tandemly inverted sites. The purpose of thi...
Saved in:
Published in | PloS one Vol. 11; no. 8; p. e0161432 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
17.08.2016
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Group E members of the SOX transcription factor family include SOX8, SOX9, and SOX10. Preceding the high mobility group (HMG) domain in each of these proteins is a thirty-eight amino acid region that supports the formation of dimers on promoters containing tandemly inverted sites. The purpose of this study was to obtain new structural insights into how the dimerization region functions with the HMG domain. From a mutagenic scan of the dimerization region, the most essential amino acids of the dimerization region were clustered on the hydrophobic face of a single, predicted amphipathic helix. Consistent with our hypothesis that the dimerization region directly contacts the HMG domain, a peptide corresponding to the dimerization region bound a preassembled HMG-DNA complex. Sequence conservation among Group E members served as a basis to identify two surface exposed amino acids in the HMG domain of SOX9 that were necessary for dimerization. These data were combined to make a molecular model that places the dimerization region of one SOX9 protein onto the HMG domain of another SOX9 protein situated at the opposing site of a tandem promoter. The model provides a detailed foundation for assessing the impact of mutations on SOX Group E transcription factors. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: The authors note that one author, JN, is employed by a commercial company: Sanofi-Pasteur Pharmaceuticals. This company did not provide a salary for the author and did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This commercial affiliation does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. Current address: McEwen Centre for Regenerative Medicine, Ontario Cancer Institute, Toronto, ON Canada Current address: Sanofi-Pasteur Pharmaceuticals, Toronto, ON, Canada Conceptualization: LWD. Formal analysis: SNR JN SS. Funding acquisition: LWD. Investigation: SNR JN SS AV NK JJK LWD. Methodology: SNR JN SS AV LWD. Software: LWD. Supervision: LWD. Validation: SNR JN SS AV LWD. Visualization: SNR JN SS AV LWD. Writing - original draft: LWD. Writing - review & editing: LWD. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0161432 |